Big Pharma’s Alzheimer’s gold rush: 35 new drugs to hit the market in the next few years as the drug cartels cash in on cognitive decline

‘It’s no big secret that the pharmaceutical industry isn’t at all concerned with trying to advance the cause of improving public health by identifying the causes of age-related cognitive decline. But it sure is banking on raking in a windfall of profits trying to treating it, with the latest figures showing that pharmaceutical companies as a whole plan to release as many as 35 new drugs over the next five years to treat Alzheimer’s disease and other forms of dementia.
These multinational corporations are literally racing against one another to be the first to release these “blockbuster” drugs, which stand to generate billions of dollars in new profits for the legal drug cartels. Alzheimer’s, it turns out, is the next big market for the pharmaceutical kingpins, which up until now have had a difficult time producing drugs that actually work and are safe.
“The Alzheimer’s disease pipeline, marred by decades of failures and underinvestment, is due for big victories,” says George Vradenburg, co-founder and chairman of the group UsAgainstAlzheimer’s.’
Read more: Big Pharma’s Alzheimer’s gold rush: 35 new drugs to hit the market in the next few years as the drug cartels cash in on cognitive decline

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.